Terms: = Lymphoma AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978
76 results:
1. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Kubota Y; Gu X; Terkawi L; Bodo J; Przychodzen BP; Awada H; Williams N; Gurnari C; Kawashima N; Aly M; Durmaz A; Mori M; Ponvilawan B; Kewan T; Bahaj W; Meggendorfer M; Jha BK; Visconte V; Rogers HJ; Haferlach T; Maciejewski JP
Nat Commun; 2024 Feb; 15(1):1832. PubMed ID: 38418452
[TBL] [Abstract] [Full Text] [Related]
3. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of persisting DNMT3A, asxl1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
Lai X; Xiao J; Wang T; Hou C; Chen J; Wu D; Xu Y
Leuk Lymphoma; 2024 Mar; 65(3):363-371. PubMed ID: 37990829
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract] [Full Text] [Related]
6. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
7. Real-world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system.
Byrd JC; Gatz JL; Louis CL; Mims AS; Borate U; Yocum AO; Gana TJ; Burd A
Cancer Med; 2023 Sep; 12(17):18368-18380. PubMed ID: 37635639
[TBL] [Abstract] [Full Text] [Related]
8. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia.
Jain AG; Ball S; Aguirre LE; Tobon KA; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman D; Lancet JE; Sweet K
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e315-e322. PubMed ID: 37558530
[TBL] [Abstract] [Full Text] [Related]
9. Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia.
Marinelli LM; Romain JT; Ehman W; Ortega V; Velagaleti G; Gibbons TF; Nazario-Toole A; Holmes AR
Cancer Genet; 2023 Aug; 276-277():43-47. PubMed ID: 37480761
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Jelloul FZ; Quesada AE; Yang RK; Li S; Wang W; Xu J; Tang G; Yin CC; Fang H; El Hussein S; Khoury J; Bassett RL; Garcia-Manero G; Manasanch EE; Orlowski RZ; Qazilbash MH; Patel KP; Medeiros LJ; Lin P
Mod Pathol; 2023 Jun; 36(6):100166. PubMed ID: 36990279
[TBL] [Abstract] [Full Text] [Related]
12. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract] [Full Text] [Related]
13. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
[TBL] [Abstract] [Full Text] [Related]
14. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
Tinsley-Vance SM; Ali NA; Ball S; Aguirre LE; Jain AG; Hussaini MO; Chan O; Kuykendall A; Sweet K; Lancet J; Padron E; Sallman DA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):355-359. PubMed ID: 36813626
[TBL] [Abstract] [Full Text] [Related]
15. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
Testa S; Kumar J; Goodell AJ; Zehnder JL; Alexander KM; Sidana S; Arai S; Witteles RM; Liedtke M
Semin Oncol; 2022 Dec; 49(6):465-475. PubMed ID: 36503855
[TBL] [Abstract] [Full Text] [Related]
16. Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia.
Ye MT; Wang Y; Zuo Z; Calin S; He H; Tang Z; Jabbour EJ; Borthakur G; Zhang Y; Yang Y; You MJ
Cancer; 2023 Jan; 129(1):49-59. PubMed ID: 36281717
[TBL] [Abstract] [Full Text] [Related]
17. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M; Derkach A; Farnoud N; Bewersdorf JP; Robinson T; Famulare C; Cho C; Devlin S; Menghrajani K; Patel MA; Cai SF; Miles LA; Bowman RL; Geyer MB; Dunbar A; Epstein-Peterson ZD; McGovern E; Schulman J; Glass JL; Taylor J; Viny AD; Stein EM; Getta B; Arcila ME; Gao Q; Barker J; Shaffer BC; Papadopoulos EB; Gyurkocza B; Perales MA; Abdel-Wahab O; Levine RL; Giralt SA; Zhang Y; Xiao W; Pai N; Papaemmanuil E; Tallman MS; Roshal M; Goldberg AD
Am J Hematol; 2023 Jan; 98(1):79-89. PubMed ID: 36251406
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Landscape of Mixed-Phenotype Acute Leukemia.
Hennawi M; Pakasticali N; Tashkandi H; Hussaini M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232559
[TBL] [Abstract] [Full Text] [Related]
19. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
[TBL] [Abstract] [Full Text] [Related]
20. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
Larkin KT; Nicolet D; Kelly BJ; Mrózek K; LaHaye S; Miller KE; Wijeratne S; Wheeler G; Kohlschmidt J; Blachly JS; Mims AS; Walker CJ; Oakes CC; Orwick S; Boateng I; Buss J; Heyrosa A; Desai H; Carroll AJ; Blum W; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Stone RM; Paskett ED; Byrd JC; Mardis ER; Eisfeld AK
Blood Adv; 2022 Oct; 6(19):5570-5581. PubMed ID: 35788257
[TBL] [Abstract] [Full Text] [Related]
[Next]
